# An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)

> **NCT03769168** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 55 (actual)

## Conditions studied

- Juvenile Psoriatic Arthritis
- Enthesitis Related Arthritis

## Interventions

- **DRUG:** Secukinumab

## Key facts

- **NCT ID:** NCT03769168
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-07
- **Primary completion:** 2024-11-07
- **Final completion:** 2024-11-07
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2025-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03769168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03769168, "An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03769168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*